Erratum

Abstract

Figure 2 Timeline illustrating the different categories assigned to a single pharmaceutical agent (pembrolizumab) based on the life cycle of drug development, regulatory medicines authority approval, and government subsidisation, for the specific trialled indication. KEYNOTE-087 and KEYNOTE204 are relapsed or refractory classic Hodgkin Lymphoma trials involving Pembrolizumab conducted at this study site. The period between 10 June 2015 and 14 March 2017 represents the financial benefit from early access to subsequently approved investigational new drugs (IND) (light blue). The time between 14 March 2017 and 1 May 2018 represents financial benefit from accessing approved medications that are not Pharmaceutical Benefits Scheme (PBS)-listed (dark blue). Cost avoidance is assigned to dispensing after its PBS listing from the 1st of May 2018 (grey bar).